Anticoagulation is the cornerstone of treatment for thrombosis and thromboembolic complications of a variety of disorders. It is estimated that over 6 million patients in the United States are treated with anticoagulants, and are thus at increased risk of bleeding with substantially increased morbidity and mortality. Secular trends in anticoagulation use have demonstrated a relatively rapid adoption of direct oral anticoagulants (DOACs) for the most common indications for anticoagulation: AF in the absence of a prosthetic valve and venous thromboembolism. Systematic reviews have demonstrated favorable risk-benefit profiles for DOACs when compared with vitamin K antagonists (VKAs) in the management of AF and with low-molecular-weight heparin in the treatment and prevention of venous thromboembolism. The favorable outcomes with DOACs and the emergence of reversal agents may also further increase the proportionate use of DOACs and influence the management of bleeding that complicates anticoagulant use.
This webinar will examine the consensus results through use of a detailed patient case study, incorporating discussion of consensus findings.
Guest Discussant: Adam Cuker, MD, MS
Moderators: Tracy Minichiello, MD; Sara Vazquez, PharmD